Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sagent Buys Out China JV | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sagent Buys Out China JV

Gains full control of cGMP manufacturing facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sagent Pharmaceuticals will acquire the remaining 50% interest of its joint venture partner, Chengdu Kanghong Pharmaceuticals Co. Ltd., in the Kanghong Sagent (Chengdu) Pharmaceutical Corp. Ltd. (KSCP) joint venture. KSCP will become a wholly-owned subsidiary of Sagent. The $25 million acquisition, subject to customary closing conditions, is expected to close within the next several months.
 
“We originally formed our joint venture in 2006 to construct and operate an FDA and cGMP compliant, sterile manufacturing facility in Chengdu, China,” said Jeffrey M. Yordon, chief executive officer and chairman of the board of Sagent. “Our partnership with Kanghong was instrumental in helping us navigate the construction and start-up of this facility, which provided us with dedicated manufacturing capacity utilizing isolator technology for aseptic filling. Over the last couple of years, however, we recognized that having full control of the facility better serves Sagent’s long-term strategic goals, including a strategy of additional investment in product development and capacity expansion. The facility was inspected by the FDA in 2012 and has been deemed acceptable for product approvals, which we expect in 2013.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics